Blackstone Life Sciences - aVenture Asset Manager Research
Blackstone Life Sciences
Operating Status: Operating
Cambridge-based BXLS provides vital funding to life sciences, aiding in healthcare innovation.
Location
Cambridge, MA, US
Founded
2005
Blackstone Life Sciences (BXLS) is a Cambridge-based investment firm focused on the life sciences sector. They provide critical funding to pharmaceutical, biotechnology, and medical technology companies, addressing the gap between scientific innovation and market-ready healthcare solutions. BXLS typically invests in post-IPO equity rounds, with occasional participation in Series A and post-IPO debt financing.
Notable portfolio companies include Alnylam Pharmaceuticals, Amicus Therapeutics, and Medtronic. BXLS's investment philosophy centers on partnering with industry leaders to advance medical breakthroughs and healthcare technologies. As part of the larger Blackstone Group, BXLS leverages extensive resources and expertise to support its portfolio companies in bringing innovative medicines and technologies to market.
Blackstone Life Sciences - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies8
Current Portfolio Count8
Top Investment Stages
Series A1 (100.0%)
Stage Mix
Series A 100%
Concentration shown as share of disclosed investments by stage.
